Newsfile Corp
29 Jul 2026, 13:41 UTC · 7h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is alleged to have used a channel-stuffing scheme to report 20% revenue growth in 2025 when it may have actually experienced a 3% decline. — Allegations of systemic revenue manipulation and artificial growth are fundamental red flags that typically lead to severe valuation resets and loss of investor trust.
-0.90A class action lawsuit has been filed against ADMA Biologics by Berger Montague PC on behalf of investors who purchased stock between August 9, 2024, and March 25, 2026. — Class action lawsuits introduce significant legal liability, potential settlement costs, and ongoing management distraction.
-0.50The lawsuit alleges that ADMA Biologics failed to disclose related party transactions. — Failure to disclose related party transactions suggests poor corporate governance and potential conflicts of interest.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit alleging a channel-stuffing scheme to inflate revenue growth.
The company is mentioned in a reminder for investors to inquire about a securities fraud lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
